Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
Go back to Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
March 26, 2024 11:20 AM EDT
BTIG analyst Justin Zelin raised the price target on Viking Therapeutic (NASDAQ: VKTX) to $125.00 (from $100.00) while maintaining a Buy rating.
The analyst commented, "Viking is up +~25% (vs +0.75% XBI) this morning following presentation of impressive first in human data for oral VK2735, demonstrating 3.3% pbo adj weight loss in the highest dose cohort (40mg QD, n=7) at 28-days with an... More
March 26, 2024 7:09 AM EDT
Viking Therapeutics (NASDAQ: VKTX) Climbs 10% Following Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
Up to 3.3% Placebo-Adjusted Mean Weight Loss (5.3% from Baseline) Observed After 28 DaysVK2735 Shown to be Safe and Well-Tolerated in 28-Day...
More
